Purchase this article with an account.
L. Hoffart, F. Matonti, F. Chavane, G. Masson, Hé. Proust, B. Ridings, J. Conrath; Prevention of Corneal Neovascularization by Anti-VEGF Therapy in an Experimental Rat Model. Invest. Ophthalmol. Vis. Sci. 2007;48(13):1697.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effect of topically administeredanti-VEGF therapy on experimental corneal neovascularization in rats.
Chemical cauterization of cornea was performed in 20eyes of 20 rats by using silver nitrate/potassium nitrate sticks. Cauterization was followed by a single subconjunctival injection of bevacizumab (avastin®) in 10 rats (group 1) and by a single subconjunctival injection of BSS in 10 rats (group 2). Percent areas of cornea covered by neovascularization and covered by scar in each group were calculated by use of computer software on digital photographs at J0, J7, J14, J21 and J28. Groups were compared for any significant (P , 0.05) differences among them. Animals were euthanized and cauterized eyes were enucleated and fixed in formaldehyde 10% for histologic examination using hematoxylinand eosin staining.
The bevacizumab (avastin®) group was different from control group (P , 0.05). There were no significant differences in percent area of corneal scar among groups. Further studies are needed to compare anti-VEGF therapy versus corticosteroids in preventing corneal neovacularization in rats after chemical cauterization .
Topical instillation of bevacizumab (avastin®) seems to diminish corneal neovascularization caused by chemical cauterization of cornea in rats.
This PDF is available to Subscribers Only